TY - JOUR T1 -现实世界mepolizumab在前瞻性重度哮喘中的应用初步分析JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00151 -2020欧元六世- 56 - 4 SP - 2000151 AU -哈里森,蒂姆•AU - Canonica乔治•沃尔特盟——Chupp杰弗里AU -李,杰森盟——Schleich佛罗伦萨盟——Welte Tobias AU -瓦莱罗能源,安东尼奥盟——Gemzoe金盟——麦克斯韦Aoife盟——Joksaite桑德拉AU -杨,Shibing盟——霍沃斯、彼得AU -范戴克,Melissa K. Y1 - 2020/10/01 UR - //www.qdcxjkg.com/content/56/4/2000151.abstract N2 -介绍抗白介素-5单克隆抗体mepolizumab的疗效在随机对照试验中得到证实;关于它在日常临床实践中对现实世界的影响的数据开始出现。我们评估了现实世界中为患者开出的mepolizumab的有效性和安全性。REALITI-A是一项全球性、前瞻性、观察性队列研究，收集哮喘患者常规医疗就诊的数据。纳入新使用美泊珠单抗治疗严重哮喘且在美泊珠单抗治疗前有12个月相关病史的患者(回顾性收集)。对完成1年随访(截至2019年2月28日)的早期发起人的数据进行了初步分析。主要目的是比较mepolizumab前后临床显著恶化(需要口服皮质类固醇(OCS)和/或住院和/或急诊科就诊)的发生率;需要住院和/或急诊科就诊的病情加重和维持OCS使用的改变是次要目标。 Treatment-related adverse events were reported.Results Overall, 368 mepolizumab-treated patients were included. Rates of clinically significant exacerbations were reduced by 69% from 4.63 per person per year pre-treatment to 1.43 per person per year during follow-up (p<0.001), as were those requiring hospitalisation and/or emergency department visit (from 1.14 to 0.27 per person per year; 77% reduction). In 159 patients with maintenance OCS dose data available during the pre-treatment period, median daily dose decreased from 10.0 (pre-treatment) to 5.0 mg·day−1 by week 21–24 of follow-up, sustained until week 53–56. No new safety signals were reported.Conclusion These data demonstrate that the effectiveness of mepolizumab is consistent with clinical trial results under real-world settings, with significant reductions in exacerbations and daily maintenance OCS dose.Mepolizumab has demonstrated efficacy in patients with severe eosinophilic asthma in the controlled environment of clinical trials. These initial data from the prospective REALITI-A study show that similar results are obtained in a real-world setting. https://bit.ly/3hINnFO ER -